FY2017 Earnings Estimate for Pacific Biosciences of California, Inc. (PACB) Issued By William Blair

0

Pacific Biosciences of California, Inc. (NASDAQ:PACB) – Analysts at William Blair raised their FY2017 earnings estimates for Pacific Biosciences of California in a note issued to investors on Tuesday. William Blair analyst A. Murphy now forecasts that the biotechnology company will earn ($0.89) per share for the year, up from their prior forecast of ($0.95). William Blair also issued estimates for Pacific Biosciences of California’s Q4 2017 earnings at ($0.19) EPS, Q1 2018 earnings at ($0.16) EPS, Q2 2018 earnings at ($0.16) EPS, Q3 2018 earnings at ($0.14) EPS, Q4 2018 earnings at ($0.14) EPS, FY2018 earnings at ($0.60) EPS and FY2019 earnings at ($0.42) EPS.

PACB has been the topic of a number of other research reports. First Analysis lowered shares of Pacific Biosciences of California from an “overweight” rating to an “equal weight” rating and set a $4.00 price target on the stock. in a report on Friday, November 3rd. CL King lowered shares of Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 price target on the stock. in a report on Thursday, September 28th. BidaskClub lowered shares of Pacific Biosciences of California from a “sell” rating to a “strong sell” rating in a report on Thursday, July 27th. Finally, Zacks Investment Research upgraded shares of Pacific Biosciences of California from a “sell” rating to a “hold” rating in a report on Thursday. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $6.27.

This story was first posted by GBand is owned by of DT GB gearsofbiz this story , US and The of this story 2017/11/10/fy2017-earnings-estimate-for-pacific-biosciences-of-california-inc-pacb-issued-by-william-blair

Shares of Pacific Biosciences of California (NASDAQ PACB) traded up $0.06 during trading hours on Friday, hitting $2.94. 497,244 shares of the stock were exchanged, compared to its average volume of 966,195. The company has a current ratio of 3.75, a quick ratio of 3.15 and a debt-to-equity ratio of 0.10. Pacific Biosciences of California has a 52 week low of $2.66 and a 52 week high of $8.32.

Pacific Biosciences of California (NASDAQ:PACB) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. The firm had revenue of $23.54 million for the quarter, compared to analysts’ expectations of $28.29 million. Pacific Biosciences of California had a negative net margin of 95.97% and a negative return on equity of 97.50%. The company’s revenue was down 6.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.19) earnings per share.

Several large investors have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its holdings in shares of Pacific Biosciences of California by 23.2% during the third quarter. Bank of New York Mellon Corp now owns 459,558 shares of the biotechnology company’s stock worth $2,412,000 after purchasing an additional 86,415 shares during the period. Aperio Group LLC lifted its holdings in Pacific Biosciences of California by 105.5% in the third quarter. Aperio Group LLC now owns 42,396 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 21,766 shares during the period. Mutual of America Capital Management LLC lifted its holdings in Pacific Biosciences of California by 2.8% in the third quarter. Mutual of America Capital Management LLC now owns 482,088 shares of the biotechnology company’s stock valued at $2,531,000 after buying an additional 13,181 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Pacific Biosciences of California by 7.9% in the second quarter. The Manufacturers Life Insurance Company now owns 70,533 shares of the biotechnology company’s stock valued at $250,000 after buying an additional 5,145 shares during the period. Finally, BlueCrest Capital Management Ltd acquired a new position in Pacific Biosciences of California in the second quarter valued at $155,000. Institutional investors own 68.09% of the company’s stock.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Earnings History and Estimates for Pacific Biosciences of California (NASDAQ:PACB)




Receive News & Ratings for Pacific Biosciences of California Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pacific Biosciences of California Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Share.

Leave A Reply